<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/264782-arylalkylcarbamate-derivatives-and-processes-for-preparation-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:47:51 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 264782:ARYLALKYLCARBAMATE DERIVATIVES AND PROCESSES FOR PREPARATION THEREOF</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">ARYLALKYLCARBAMATE DERIVATIVES AND PROCESSES FOR PREPARATION THEREOF</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to a compound having general formula (I), wherein: n represents an integer of between 1 and 6; A is selected from one or more X, Y and/or Z groups; X represents an optionally-substituted C1-2-alkylene group; Y represents an optionally-substituted C2-alkenylene group or a -C&lt;u&gt;=&lt;/u&gt;C- group; Z represents a C3-7-cycloalkyl group having formula (II) in which m represents an integer of between 1 and 5, and p and q represent integers and are defined such that p+q equals a number of between 1 and 5; R1 represents a hydrogen atom, a halogen atom or a hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-thioalkyl, C1-3-fluoroalkyl, C1-3-fluoroalkoxy, C1-3-fluorothioalkyl group; R2 represents a hydrogen atom, a halogen atom or a cyano, nitro, hydroxyl, C1-3-alkyl, C1-3-alkoxy, C1-3-thioalkyl, C1-3-fluoroalkyl, C1-3-fluoroalkoxy, C1-3-fluorothioalkyl group, or an optionally-substituted aromatic or heteroaromatic group; R3 represents either a 2,2,2-trifluoroethyl group or an optionally-substituted phenyl group; and R6 and R7 represent independently of each other a C1-3-alkyl group, a phenyl; said compound taking the form of a base, an acid addition salt, a hydrate or a solvate. The invention also relates to the use of the compound in therapeutics.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The invention relates to arylalkylcarbamate<br>
derivatives, to the preparation thereof and to the use<br>
thereof in therapeutics.<br>
The compounds of the invention correspond to general<br>
formula (I):<br><br>
in which<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group -C≡C-<br><br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or C1-3-<br><br>
fluorothioalkyl group;<br>
R2 represents<br>
a hydrogen atom, a halogen atom,<br>
or a cyano, nitro, hydroxyl, C1-3-alkyl, C1-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-fluoroalkyl, C1-3-f luoroalkoxy or<br>
C1-3-fluorothioalkyl group;<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl,<br>
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,<br>
thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl,<br>
benzofuryl, dibenzofuryl, benzimidazolyl, benzo-<br>
triazolyl, indolyl, isoindolyl, indazolyl,<br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl, benziso-<br>
thiazolyl, dihydroindolyl, pyrrolopyridinyl, furo-<br>
pyridinyl, thienopyridinyl, imidazopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, naphthalenyl-<br>
propoxy, quinolinoxy and isoquinolinoxy, and optionally<br>
substituted with one or more substituents chosen from a<br>
halogen atom, and the following groups: hydroxyl,<br>
cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl,<br>
C1-3-fluoroalkyl, C1-3-f luoroalkoxy, C1-3- fluorothioalkyl,<br>
phenyloxy, benzyloxy, piperidyl, pyrrolidinyl,<br>
morpholinyl, NH2, NHR6, NR6R7, NHCOR6, COR6, CO2RS, SO2R6,<br>
-O- (C1-3-alkylene) -O-, 4-piperazinyl optionally<br>
substituted with a C1-3-alkyl or with a benzyl;<br>
R3 represents<br>
either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or trifluoromethoxy groups,<br><br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl. .<br>
In the context of the invention,	the compounds of<br>
general formula (I) can therefore	comprise several<br>
groups A which may be identical to	or different from<br>
one another.<br>
The following compounds are not part of the invention:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-nitrophenyl 2-[4-(phenylmethoxy)phenyl]ethyl-<br>
carbamate;<br>
-	4-chloro-2-nitrophenyl 2-(4-(chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2- (3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	phenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	4-cyanophenyl 2-(4-methylphenyl)ethylcarbamate;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate,•<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo-<br>
[4,5-b]pyridin-3-yl)phenyl]ethylcarbamate;<br>
-	phenyl 2-[4-(3-thienyl)phenyl]propylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate.<br>
Among the compounds of general formula (I) , a first<br>
subgroup of compounds consists of the compounds for<br>
which:<br><br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally-<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents<br>
a halogen atom, or a nitro, hydroxyl, C1-3-alkyl or C1-3-<br>
alkoxy group; and<br>
R3 represents<br>
either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms, or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or trifluoromethoxy groups.<br>
The following compounds are not part of the first<br>
subgroup of compounds above:<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-chloro-2-nitrophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	phenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br><br>
-	4-cyanophenyl 2-(4-methylphenyl)ethylcarbamate;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chloropbenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate.<br>
Among the compounds of the general formula (I) , a<br>
second subgroup of compounds consists of the compounds<br>
for which:<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-s-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br><br>
R2 represents<br>
a hydrogen atom, or a cyano, C1-3-thioalkyl, C1-3-<br>
fluoroalkyl, C1-3-fluoroalkoxy or C1-3-f luorothioalkyl<br>
group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, guinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl,<br>
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,<br>
thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl,<br>
benzofuryl, dibenzofuryl, benzimidazolyl, benzo-<br>
triazolyl, indolyl, isoindolyl, indazolyl,<br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl, benziso-<br>
thiazolyl, dihydroindolyl, pyrrolopyridinyl, furo-<br>
pyridinyl, thienopyridinyl, imidazopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, naphthalenyl-<br>
propoxy, quinolinoxy and isoquinolinoxy, and optionally<br>
substituted with one or more substituents chosen from a<br>
halogen atom, and the following groups: hydroxyl,<br>
cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl,<br>
C1-3-fluoroalkyl, C1-3-f luoroalkoxy, C1-3-f luorothioalkyl,<br>
phenyloxy, benzyloxy, piperidyl, pyrrolidinyl,<br>
morpholinyl, NH2, NHRe, NR6R7, NHCOR6, COR5, C02R6, SO2R6,<br>
-O-(C1-3-alkylene)-O-, 4-piperazinyl optionally<br>
substituted with a C1-3-alkyl or with a benzyl;<br>
R3 represents<br>
either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or trifluoromethoxy groups,<br>
and<br>
R6 and R7 represent, independently of one another, a<br><br>
C1-3-alkyl group or a phenyl.<br>
The following compounds are not part of the second<br>
subgroup of compounds above:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	4-nitrophenyl 2-[4-(phenylmethoxy)phenyl]ethyl-<br>
carbamate;<br>
-	phenyl 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]-<br>
pyridin-3-yl)phenyl]ethylcarbamate;<br>
-	phenyl 2-[4-(3-thienyl)phenyl]propylcarbamate;<br>
-	phenyl 2- [4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate .<br>
Among the compounds of general formula (I) , a first<br>
family of compounds consists of the compounds for<br>
which:<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-fluoroalkyl, C1-3-fluoroalkoxy or C1-3-<br><br>
fluorothioalkyl group;<br>
R2 represents<br>
a hydrogen atom, a halogen atom,<br>
or a cyano, nitro, hydroxyl, C1-3-alkyl, C1-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-fluoroalkyl, C1-3-f luoroalkoxy or<br>
C1-3-fluorothioalkyl group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl,<br>
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,<br>
thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl,<br>
benzofuryl, dibenzofuryl, benzimidazolyl, benzo-<br>
triazolyl, indolyl, isoindolyl, indazolyl,<br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl, benziso-<br>
thiazolyl, dihydroindolyl, pyrrolopyridinyl, furo-<br>
pyridinyl, thienopyridinyl, imidazopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, naphthalenyl-<br>
propoxy, quinolinoxy and isoquinolinoxy, and optionally<br>
substituted with one or more substituents chosen from a<br>
halogen atom, and the following groups: hydroxyl,<br>
cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl,<br>
C1-3-fluoroalkyl, C1-3-f luoroalkoxy, C1-3-f luorothioalkyl,<br>
phenyloxy, benzyloxy, piperidyl, pyrrolidinyl,<br>
morpholinyl, NH2, NHR6, NR6R7, NHCOR6, COR6, CO2R6, SO2R6,<br>
-O-(Ca-3-alkylene)-O-, 4-piperazinyl optionally<br>
substituted with a C1-3-alkyl or with a benzyl;<br>
R3 represents<br>
either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or trifluoromethoxy groups,<br><br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl;<br>
on the condition that<br>
when R3 represents a phenyl group,<br>
if A represents a propylene, then R2 does not represent<br>
a thienyl.<br>
The following compounds are not part of the first<br>
family of compounds defined above:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-nitrophenyl 2-[4-(phenylmethoxy)phenyl]ethyl-<br>
carbamate;<br>
-	4-chloro-2-nitrophenyl 2- (4-(chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	phenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	4-cyanophenyl 2-(4-methylphenyl)ethylcarbamate;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2- [4-(2-ethyl-5,7-dimethyl-3H-imidazo-<br>
[4,5-b]pyridin-3-yl)phenyl]ethylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate.<br>
Among the compounds of general formula (I) , a second<br>
family of compounds consists of the compounds for<br>
which:<br>
-	when R3 represents a 2,2,2-trifluoroethyl group, then<br><br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-fluoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents<br>
a hydrogen atom, a halogen atom,<br>
or a cyano, nitro, hydroxyl, C1-3-alkyl, C1-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or<br>
C1-3-fluorothioalkyl group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl,<br>
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,<br>
thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl,<br>
benzofuryl, dibenzofuryl, benzimidazolyl, benzo-<br>
triazolyl, indolyl, isoindolyl, indazolyl,<br><br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl, benziso-<br>
thiazolyl, dihydroindolyl, pyrrolopyridinyl, furo-<br>
pyridinyl, thienopyridinyl, imidazopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, naphthalenyl-<br>
propoxy, quinolinoxy and isoquinolinoxy, and optionally<br>
substituted with one or more substituents chosen from a<br>
halogen atom, and the following groups: hydroxyl,<br>
cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl,<br>
C1-3-fluoroalkyl, C1-3-f luoroalkoxy, C1-3-f luorothioalkyl,<br>
phenyloxy, benzyloxy, piperidyl, pyrrolidinyl,<br>
morpholinyl, NH2, NHRS, NR6R7, NHCOR6, COR6l CO2R6, SO2R6,<br>
-O-(C1-3-alkylene)-O-, 4-piperazinyl optionally<br>
substituted with a C1-3-alkyl or with a benzyl; and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl;<br>
- when R3 represents a phenyl group optionally<br>
substituted with one or more halogen atoms, or cyano,<br>
nitro, C1-3-alkyl, C1-3-alkoxy, trifluoromethyl or<br>
trifluoromethoxy groups, then<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br><br>
m represents an integer ranging from 1 to 5;<br>
p and g represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-fluoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents<br>
a hydrogen atom, a halogen atom,<br>
or a cyano, nitro, hydroxyl<br>
, C1-3-alkyl, C1-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or<br>
C1-3-fluorothioalkyl group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
furyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl,<br>
thiazolyl, isoxazolyl, isothiazolyl, thiadiazolyl,<br>
oxadiazolyl, triazolyl, benzothienyl, benzofuryl,<br>
dibenzofuryl, benzimidazolyl, benzotriazolyl, indolyl,<br>
isoindolyl, indazolyl, benzoxazolyl, benzisoxazolyl,<br>
benzothiazolyl, benzisothiazolyl, dihydroindolyl,<br>
pyrrolopyridinyl, furopyridinyl, thienopyridinyl,<br>
imidazopyridinyl, oxazolopyridinyl, thiazolopyridinyl,<br>
pyrazolopyridinyl,	isoxazolopyridinyl,<br>
isothiazolopyridinyl,	tetrahydroquinolinyl,<br>
tetrahydroisoquinolinyl, phenyloxy, phenylthio,<br>
phenylsulfonyl, benzoyl, phenylmethoxy, phenylethoxy,<br>
phenylpropoxy, naphthalenyloxy, naphthalenylmethoxy,<br>
naphthalenylethoxy, naphthalenylpropoxy, quinolinoxy<br>
and isoquinolinoxy, and optionally substituted with one<br>
or more substituents chosen from a halogen atom, and<br><br>
the following groups: hydroxyl, cyano, nitro, C1-4-<br>
alkyl, C1-4-alkoxy, C1-4-thioalkyl, C1-3-f luoroalkyl, C1-3-<br>
fluoroalkoxy, C1-3-fluorothioalkyl, phenyloxy,<br>
benzyloxy, piperidyl, pyrrolidinyl, morpholinyl, NH2,<br>
NHR6, NReR7, NHCOR6, COR6, CO2R6, S02Rs, -O-(C1-3-<br>
alkylene)-O-, 4-piperazinyl optionally substituted with<br>
a C1-3-alkyl or with a benzyl; and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl.<br>
The following compounds are not part of the second<br>
family of compounds defined above:<br>
-	2,2 ,2-trifluoroethyl benzylcarbamate;<br>
-	2,2 , 2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-nitrophenyl 2- [4- (phenylmethoxy)phenyl]ethyl-<br>
carbamate;<br>
-	4-chloro-2-nitrophenyl 2-(4-(chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate ;<br>
-	phenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	4-cyanophenyl 2-(4-methylphenyl)ethylcarbamate;<br>
-	2,4, 5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo-<br>
[4,5-b]pyridin-3-yl)phenyl]ethylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate.<br>
Among the compounds of general formula (I) , a third<br>
family of compounds consists of the compounds for<br><br>
which:<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents<br>
a hydrogen atom, a halogen atom,<br>
or a cyano, nitro, hydroxyl, C1-3-alkyl, C1-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or<br>
C1-3-fluorothioalkyl group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl,<br>
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,<br>
thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl,<br>
benzofuryl, dibenzofuryl, benzimidazolyl, benzo-<br><br>
triazolyl, indolyl, isoindolyl, indazolyl,<br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl, benziso-<br>
thiazolyl, dihydroindolyl, pyrrolopyridinyl, furo-<br>
pyridinyl, thienopyridinyl, imidazopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, naphthalenyl-<br>
propoxy, quinolinoxy and isoquinolinoxy, and optionally<br>
substituted with one or more substituents chosen from a<br>
halogen atom, and the following groups: hydroxyl,<br>
cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl,<br>
C1-3-f luoroalkyl, C1-3-f luoroalkoxy, C1-3-f luorothioalkyl,<br>
phenyloxy, benzyloxy, piperidyl, pyrrolidinyl,<br>
morpholinyl, NH2, NHR6, NR6R7, NHCOR6, COR6, CO2R6, SO2R6,<br>
-O-(C1-3-alkylene)-O-, 4-piperazinyl optionally<br>
substituted with a C1-3-alkyl or with a benzyl;<br>
R3 represents<br>
either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms, or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or trifluoromethoxy groups,<br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl;<br>
on the condition that<br>
-	when R3 represents a 2,2,2-trifluoroethyl group,<br>
if A represents a methylene and if Ri represents a<br>
hydrogen, then R2 is neither a hydrogen nor a methoxy;<br>
if A represents a methylene and if R2 represents a<br>
hydrogen, then R1 is neither a hydrogen nor a methoxy;<br>
-	when R3 represents a phenyl group,<br>
if A represents a methylene, then neither R1 nor R2<br>
represents a chlorine atom, a methoxy group or a nitro<br>
group;<br>
if A represents an ethylene, then<br>
neither R1 nor R2 represents a methoxy;<br><br>
R2 represents neither a 2-ethyl-5,7-dimethyl-3H-<br>
imidazo[4,5-b]pyridin-3-yl nor a 2-amino-4-thiazolyl;<br>
if A represents a propylene, then R2 does not represent<br>
a 3-thienyl;<br>
-	when R3 represents a phenyl group substituted with<br>
one to five chlorine or fluorine atoms or nitro or<br>
cyano groups,<br>
if A represents a methylene, then neither R1 nor R2<br>
represents a methoxy or a bromine atom;<br>
if A represents an ethylene, then<br>
neither R1 nor R2 represents a chlorine atom, or a<br>
hydroxyl, methyl or methoxy group;<br>
R2 does not represent a phenylmethoxy.<br>
Among the compounds of general formula (I) , a fourth<br>
family of compounds consists of the compounds for<br>
which:<br>
-	when R3 represents a 2,2,2-trifluoroethyl group, then<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br><br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents<br>
a halogen atom<br>
or a cyano, nitro, hydroxyl, C1-3-alkyl, C2-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy or<br>
C1-3-fluorothioalkyl group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl,<br>
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,<br>
thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl,<br>
benzofuryl, dibenzofuryl, benzimidazolyl, benzo-<br>
triazolyl, indolyl, isoindolyl, indazolyl,<br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl, benziso-<br>
thiazolyl, dihydroindolyl, pyrrolopyridinyl, furo-<br>
pyridinyl, thienopyridinyl, imidazopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, naphthalenyl-<br>
propoxy, quinolinoxy and isoquinolinoxy, and optionally<br>
substituted with one or more substituents chosen from a<br>
halogen atom, and the following groups: hydroxyl,<br>
cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl,<br>
C1-3-fluoroalkyl, C1-3-f luoroalkoxy, C1-3-f luorothioalkyl,<br>
phenyloxy, benzyloxy, piperidyl, pyrrolidinyl,<br>
morpholinyl, NH2, NHRS, NR6R7, NHCOR6, COR6, CO2R6, SO2R6,<br>
-O-(C1-3-alkylene)-O-, 4-piperazinyl optionally<br>
substituted with a C1-3-alkyl or with a benzyl;<br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl;<br><br>
- when R3 represents a phenyl group optionally<br>
substituted with one or more halogen atoms, or cyano,<br>
nitro, C1-3-alkyl, C1-3-alkoxy, trif luoromethyl or<br>
trifluoromethoxy groups, then<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group<br>
-C≡C-;<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, an iodine atom, or a<br>
cyano, C2-3-alkyl, C2-3-alkoxy, C1-3-thioalkyl, C1-3-<br>
fluoroalkyl, C1-3-fluoroalkoxy or C1-3-fluorothioalkyl<br>
group;<br>
R2 represents<br>
a hydrogen atom, an iodine atom,<br>
or a cyano, C2-3-alkyl, C2-3-alkoxy, C1-3-thioalkyl, C1-3-<br>
fluoroalkyl, C1-3-f luoroalkoxy or C1-3f luorothioalkyl<br>
group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
furyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl,<br><br>
isoxazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl,<br>
triazolyl, benzothienyl, benzofuryl, dibenzofuryl,<br>
benzimidazolyl, benzotriazolyl, indolyl, isoindolyl,<br>
indazolyl, benzoxazolyl, benzisoxazolyl,<br>
benzothiazolyl, benzisothiazolyl, dihydroindolyl,<br>
pyrrolopyridinyl, furopyridinyl, thienopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylethoxy,<br>
phenylpropoxy, naphthalenyloxy, naphthalenylmethoxy,<br>
naphthalenylethoxy, naphthalenylpropoxy, quinolinoxy<br>
and isoquinolinoxy, and optionally substituted with one<br>
or more substituents chosen from a halogen atom, and<br>
the following groups: hydroxyl, cyano, nitro, Ci_4-<br>
alkyl, C1-4-alkoxy, C1-4-thioalkyl, C1-3-f luoroalkyl, Ca-3-<br>
f luoroalkoxy, C1-3-f luorothioalkyl, phenyloxy,<br>
benzyloxy, piperidyl, pyrrolidinyl, morpholinyl, NH2,<br>
NHR6, NR6R7, NHCOR6, COR6, CO2Rs, SO2R6, -O- (C1-3-<br>
alkylene)-O-, 4-piperazinyl optionally substituted with<br>
a Cx-3-alkyl or with a benzyl;<br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl.<br>
Among the compounds of general formula (I) , a fifth<br>
family of compounds consists of the compounds for<br>
which:<br>
n represents an integer between 1 and 6;<br>
A is chosen from one or more groups X, Y and/or Z;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycolalkyl-1-6-alkylene groups;<br>
Y represents a C2-alkenylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups; or a group -C≡C-<br>
7<br>
Z represents a C3-7-cycloalkyl group of formula:<br><br><br>
m represents an integer ranging from 1 to 5;<br>
p and q represent integers and are defined such that<br>
p+q is a number ranging from 1 to 5;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3-fluoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents<br>
a hydrogen atom, or a phenyl or phenyloxy group, this<br>
group being optionally substituted with one or more<br>
substituents chosen from a halogen atom, and the<br>
following groups: hydroxyl, cyano, nitro, C1-4-alkyl,<br>
C1-4-alkoxy, C1-4-thioalkyl, C1-3-f luoroalkyl, C1-3-f luoro-<br>
alkoxy, C1-3-f luorothioalkyl, phenyloxy, benzyl oxy,<br>
piperidyl, pyrrolidinyl, morpholinyl, NH2, NHR6, NR6R7,<br>
NHCOR6, COR6, CO2R6, SO2R6, -O-(C1-3-alkylene)-O-, 4-<br>
piperazinyl optionally substituted with a C1-3-alkyl or<br>
with a benzyl;<br>
R3 represents<br>
either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms, or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or trifluoromethoxy groups,<br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl;<br>
2,2,2-trifluoroethyl benzylcarbamate being excluded.<br>
Among the compounds of general formula (I) , a sixth<br>
family of compounds consists of the compounds for<br>
which:<br>
n represents an integer between 1 and 6;<br>
A is a group X;<br><br>
the groups A being identical to or different from one<br>
another when n is an integer between 2 and 6;<br>
X represents a C1-2-alkylene group optionally-<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-f luoroalkyl, C1-3 luoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents<br>
a hydrogen atom, a halogen atom,<br>
or a cyano, nitro, hydroxyl, C1-3-alkyl, C1-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-f luoroalkyl, C1-3-f luoroalkoxy, C1-3-<br>
fluorothioalkyl group,<br>
or a group chosen from a phenyl, naphthalenyl,<br>
biphenyl, phenylethylenyl, naphthylethylenyl,<br>
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,<br>
triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,<br>
thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl,<br>
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl,<br>
thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl,<br>
benzofuryl, dibenzofuryl, benzimidazolyl, benzo-<br>
triazolyl, indolyl, isoindolyl, indazolyl,<br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl, benziso-<br>
thiazolyl, dihydroindolyl, pyrrolopyridinyl, furo-<br>
pyridinyl, thienopyridinyl, imidazopyridinyl,<br>
oxazolopyridinyl, thiazolopyridinyl, pyrazolopyridinyl,<br>
isoxazolopyridinyl, isothiazolopyridinyl, tetrahydro-<br>
quinolinyl, tetrahydroisoquinolinyl, phenyloxy,<br>
phenylthio, phenylsulfonyl, benzoyl, phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, naphthalenyl-<br>
propoxy, quinolinoxy and isoquinolinoxy, and optionally<br>
substituted with one or more substituents chosen from a<br>
halogen atom, and the following groups: hydroxyl,<br>
cyano, nitro, C1-4-alkyl, C1-4-alkoxy, C1-4-thioalkyl,<br>
C1-3-f luoroalkyl, C1-3-f luoroalkoxy, C1-3-f luorothioalkyl,<br>
phenyloxy, benzyloxy, piperidyl, pyrrolidinyl,<br><br>
morpholinyl, NH2, NHR6, NR6R7, NHCOR6, COR6, CO2R6, SO2R6,<br>
-O- (C1-3-alkylene) -O-, 4-piperazinyl optionally<br>
substituted with a C1-3-alkyl or with a benzyl;<br>
R3 represents<br>
either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms, or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or trifluoromethoxy groups,<br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl;<br>
on the condition that:<br>
-	when R3 represents a 2,2,2-trifluoroethyl group and<br>
the group - [A] n- represents a -CH2- group,<br>
then R1 is other than a hydrogen atom or than a methoxy<br>
group;<br>
-	when R3 represents an optionally substituted phenyl<br>
group and the group - [A]n- represents a -CH2-, -CH2CH2-,<br>
-CH(CH3)- or -CH(CH3)-CH2- group;<br>
then R1 is other than a hydrogen or chlorine atom or<br>
than a methyl or methoxy group, and R2 is other than a<br>
hydrogen atom.<br>
The compounds of general formula (I) can comprise one<br>
or more asymmetrical carbons. They can exist in the<br>
form of enantiomers or of diastereoisomers. These<br>
enantiomers and diastereoisomers, and also mixtures<br>
thereof, including racemic mixtures, are part of the<br>
invention.<br>
The compounds of formula (I) can exist in the form of<br>
bases or of addition salts with acids. Such addition<br>
salts are part of the invention.<br>
These salts are advantageously prepared with<br>
pharmaceutically acceptable acids, but the salts of<br>
other acids useful, for example, for the purification<br>
or the isolation of the compounds of formula (I) are<br>
also part of the invention. The compounds of general<br><br>
formula (I) can be in the form of hydrates or of<br>
solvates, i.e. in the form of associations or of<br>
combinations with one or more molecules of water or<br>
with a solvent. Such hydrates and solvates are also<br>
part of the invention.<br>
In the context of the invention:<br>
the expression "Ct-Z where t and z can have the<br>
values from 1 to 12" is intended to mean a carbon-<br>
based chain that can have from t to z carbon<br>
atoms; for example, "C1-3" is intended to mean a<br>
carbon-based chain which can have from 1 to 3<br>
carbon atoms;<br>
the term "alkyl" is intended to mean a linear or<br>
branched, saturated aliphatic group; for example,<br>
a C1-3-alkyl group represents a linear or branched<br>
carbon-based chain of 1 to 3 carbon atoms, more<br>
particularly a methyl, ethyl, propyl or 1-methyl-<br>
ethyl;<br>
the term "alkylene" is intended to mean a linear<br>
or branched, saturated divalent alkyl group; for<br>
example, a C1-3-alkylene group represents a linear<br>
or branched divalent carbon-based chain of 1 to 3<br>
carbon atoms, more particularly a methylene,<br>
ethylene, 1-methylethylene or propylene;<br>
the term "cycloalkyl" is intended to mean a cyclic<br>
alkyl group; for example, a C3-5-cycloalkyl group<br>
represents a cyclic carbon-based group of 3 to 5<br>
carbon atoms, more particularly a cyclopropyl,<br>
cyclobutyl or cyclopentyl;<br>
the term "alkenylene" is intended to mean a<br>
divalent unsaturated aliphatic group, more<br>
particularly an ethylene;<br>
the term "alkoxy" is intended to mean an -O-alkyl<br>
group comprising a linear or branched, saturated<br>
aliphatic chain;<br>
the term "thioalkyl" is intended to mean an -S-<br>
alkyl group comprising a linear or branched,<br>
saturated aliphatic chain;<br><br>
the term "fluoroalkyl" is intended to mean an<br>
alkyl group in which one or more hydrogen atoms<br>
have been substituted with a fluorine atom;<br>
the term "fluoroalkoxy" in intended to mean an<br>
alkoxy group in which one or more hydrogen atoms<br>
have been substituted with a fluorine atom;<br>
the term "fluorothioalkyl" is intended to mean a<br>
thioalkyl group in which one or more hydrogen<br>
atoms have been substituted with a fluorine atom;<br>
the term "halogen atom" is intended to mean a<br>
fluorine, a chlorine, a bromine or an iodine.<br>
The compounds of the invention can be prepared<br>
according to various methods, illustrated by the<br>
schemes which follow.<br>
Thus, a first method (scheme 1) for preparing the<br>
compounds of general formula (I) consists in reacting<br>
an amine of general formula (II), in which R1, R2, n and<br>
A are as defined above, with a carbonate of general<br>
formula (III), in which U represents a hydrogen atom or<br>
a nitro group and R3 is as defined above, in a solvent<br>
such as toluene or dichloroethane, at a temperature of<br>
between 0 and 80°C.<br><br>
According to a second method, the compounds of general<br>
formula (I) for which R3 represents more particularly<br>
an optionally substituted phenyl can be prepared by<br>
reacting an amine of general formula (II), as defined<br><br>
above, with an aryl chlorof ormate of general formula<br>
(IIIa)<br><br>
where R3 represents a phenyl group optionally<br>
substituted with one or more halogen atoms, or cyano,<br>
nitro, C1-3-alkyl, C1-3-alkoxy, trif luoromethyl or<br>
trifluoromethoxy groups,<br>
in a solvent such as dichloromethane or dichloroethane<br>
in the presence of a base such as triethylamine or<br>
diisopropylethylamine, at a temperature of between 0°C<br>
and the reflux temperature of the solvent.<br>
The carbonates of general formula (III) can be prepared<br>
according to any method described in the literature,<br>
for example by reaction of an alcohol of general<br>
formula HOR3 with phenyl chloroformate or para-<br>
nitrophenyl chloroformate, in the presence of a base<br>
such as triethylamine or diisopropylethylamine.<br>
The compounds of general formulae (II) and (IIIa) are<br>
commercially available or described in the literature,<br>
or else can be prepared according to methods which are<br>
described therein or which are known to those skilled<br>
in the art.<br>
When R2 represents a group of aryl or heteroaryl type<br>
in a compound of formula (I) or (II), the introduction<br>
of R2 onto the phenyl ring can be carried out by<br>
reacting a derivative of a compound of general formula<br>
(I) or (II) in which the phenyl ring bears a chlorine,<br>
bromine or iodine atom or a trif late group, in the<br>
position where it is desired to introduce R2, with an<br>
aryl- or heteroaryl boronic acid derivative in<br><br>
accordance with the Suzuki reaction conditions (Chem.<br>
Rev. (1995), 95, 2457-2483; Angew. Chem. Int., Ed.<br>
(1999), 38, 3387-3388), or with an aryl- or heteroaryl<br>
trialkyltin derivative in accordance with the Stille<br>
reaction conditions (Angew. Chem. Int. Ed. Engl.<br>
(1986), 25, 508-524).<br>
The following examples illustrate the preparation of<br>
some compounds of the invention. They are not limiting<br>
and merely illustrate the invention. The NMR spectra<br>
and/or the LC-MS (Liquid Chromatography coupled to Mass<br>
Spectroscopy) confirm the structures and the purities<br>
of the compounds obtained.<br>
Mp (°C) represents the melting point in degrees<br>
Celsius.<br>
The numbers indicated between parentheses in the titles<br>
of the examples correspond to those of the 1st column<br>
of the table hereinafter.<br>
The IUPAC nomenclature (International Union of Pure and<br>
Applied Chemistry) was used to name the compounds in<br>
the following examples. For example, for the biphenyl<br>
group, the following numbering was observed:<br><br>
Example 1 (Compound No. 1)<br>
2,2,2-Trifluoroethyl 1,1'-biphenyl-4-ylmethylcarbamate<br>
0.119 ml (1.64 mmol) of 2,2,2-trifluoroethanol and<br>
0.306 ml (1.49 mmol) of N,N-diisopropylethylamine are<br>
added, dropwise and at ambient temperature, to a<br>
solution of 0.3 g (1.49 mmol) of para-nitrophenyl<br>
chloroformate in 15 ml of methylene chloride. The<br><br>
mixture is stirred at ambient temperature for 2 h, and<br>
then 0.275 g (1.5 mmol) of 4-phenylbenzylamine is<br>
added. N,N-Diisopropyleth.ylamine is subsequently added,<br>
dropwise and at ambient temperature, until the<br>
precipitate which has formed disappears. The<br>
transparent solution thus obtained is stirred at<br>
ambient temperature for 1 h. The reaction medium is<br>
diluted with a further 10 ml of methylene chloride and<br>
washing is carried out with a saturated aqueous<br>
ammonium chloride solution and with a saturated aqueous<br>
sodium chloride solution. The phases are separated and<br>
the organic phase is dried over sodium sulfate. The<br>
product is filtered, the filtrate is concentrated under<br>
reduced pressure and the residue is purified by silica<br>
gel chromatography with methylene chloride.<br>
0.215 g of white solid is obtained.<br>
LC-MS: 310<br>
Mp(°C): 123-125°C<br>
1H NMR (DMSO-d6) δ(ppm) : 8.25 (t, 1H) ; 7.75-7.30 (m,<br>
9H); 4.65 (q, 2H); 4.25 (d, 2H).<br>
Example 2 (Compound No. 19)<br>
2,2,2-Trifluoroethyl 2 -(1,1'-biphenyl-4-yl)ethyl-<br>
carbamate<br>
The procedure is carried out in a manner similar to<br>
Example 1, replacing the 4-phenylbenzylamine with 2- (4-<br>
biphenyl)ethylamine.<br>
0.311 g of white solid is obtained.<br>
LC-MS: 324<br>
Mp(°C): 79-81°C<br>
1H NMR (DMSO-dg) δ (ppm) : 7.80-7.20 (m, 10H) ; 4.65 (q,<br>
2H); 3.3 0 (m, 2H) ; 2.75 (t, 2H).<br><br>
Example 3 (Compound No. 10)<br>
2,2,2-Trifluoroethyl 4-phenyloxybenzylcarbamate<br>
The procedure is carried out in a manner similar to<br>
Example 1, replacing the 4-phenylbenzylamine with<br>
4-phenyloxybenzylamine.<br>
0.252 g of white solid is obtained.<br>
LC-MS: 326<br>
Mp(°C): 145-148°C<br>
1HNMR(DMSO-d6) δ(ppm): 8.15 (t, 1H) ; 7.40-6.90 (m, 9H) ;<br>
4.65 (q, 2H); 4.20 (d, 2H).<br>
Example 4 (Compound No. 3)<br>
4-Fluorophenyl 1,1'-biphenyl-4-ylmethylcarbamate<br>
0.069 ml (0.522 mmol) of 4-fluorophenyl chloroformate<br>
and 0.149 ml (0.82 mmol) of N,N-diisopropylethylamine<br>
are added, dropwise and at ambient temperature, to a<br>
solution of 0.107 g (0.58 mmol) of 4-phenylbenzylamine<br>
in 4 ml of methylene chloride. The mixture is stirred<br>
at ambient temperature for 1 h. The reaction medium is<br>
diluted with a further 2 ml of methylene chloride and<br>
washed with a saturated aqueous ammonium chloride<br>
solution and with a saturated aqueous sodium chloride<br>
solution. The phases are separated and the organic<br>
phase is filtered through a hydrophobic sintered glass<br>
funnel. The filtrate is concentrated under reduced<br>
pressure and the solid residue is washed with 5 ml of<br>
diisopropyl ether.<br>
0.136 g of white solid is obtained.<br>
LC-MS: 322<br>
Mp(°C): 155-157°C<br>
1H NMR(DMS0-d6) δ(ppm) : 8.30 (t, 1H) ; 7.70-7.10 (m,<br>
13H); 4.30 (d, 2H).<br><br>
Example 5 (Compound No. 26)<br>
4-Methylphenyl 2-(1,1'-biphenyl-4-yl)ethylcarbamate<br>
The procedure is carried out in a manner similar to<br>
Example 4, replacing the 4-phenylbenzylamine with 2-(4-<br>
biphenyl)ethylamine and the 4-fluorophenyl chloro-<br>
formate with 4-methylphenyl chloroformate.<br>
0.126 g of white solid is obtained.<br>
LC-MS: 332<br>
Mp(°C): 172-174°C<br>
1H NMR(DMSO-d6) δ(ppm) : 7.75 (t, 1H) ; 7.70-7.30 (m, 9H) ;<br>
7.10 (d, 2H); 6.90 (d, 2H); 3.30 (m, 2H); 2.80 (t, 2H);<br>
2.25 (s, 3H).<br>
Example 6 (Compound No. 16)<br>
4-Methoxyphenyl 4-phenyloxybenzylcarbamate<br>
The procedure is carried out in a manner similar to<br>
Example 4, replacing the 4-phenylbenzylamine with<br>
4-phenyloxybenzylamine and the 4-fluorophenyl<br>
chloroformate with 4-methoxyphenyl chloroformate.<br>
0.137 g of white solid is obtained.<br>
LC-MS: 350<br>
Mp(°C): 89-91°C<br>
1H NMR(DMS0-d6) δ(ppm) : 8.20 (t, 1H) ; 7.45-7.25 (m, 4H) ;<br>
7.20-6.80 (m, 9H) ; 4.25 (d, 2H) ; 3.75 (s, 3H) .<br>
The following table illustrates the chemical structures<br>
and the physical properties of some compounds according<br>
to the invention. In this table, "n.d." signifies that<br>
the melting point could not be determined (product in<br>
the form of a gum, for example).<br><br><br>
The compounds of the invention were subjected to<br>
pharmacological assays to determine their inhibitory<br>
effect on the FAAH enzyme (fatty acid amido hydrolase) .<br>
The inhibitory activity was demonstrated in a<br>
radioenzymatic assay based on measuring the product of<br>
hydrolysis (ethanolamine [1-3H] ) of anandamide<br>
[ethanolamine 1-3H] by FAAH (Life Sciences (1995), 56,<br>
1999-2005)	and (Journal of Pharmacology and<br>
Experimented Therapeutics (1997), 283, 729-734). Thus,<br>
mouse brains (minus the cerebellum) are removed and<br>
conserved at -80°C. Membrane homogenates are prepared<br>
extemporaneously by homogenization of the tissues with<br>
a Polytron in a 10mM Tris-HCl buffer (pH 8.0)<br>
containing 150 mM NaCl and 1 mM EDTA. The enzymatic<br>
reaction is subsequently carried out in 70 µl of buffer<br>
containing fatty acid-free bovine serum albumin<br>
(1 mg/ml) . The compounds tested, at various<br>
concentrations, anandamide [ethanolamine 1-3H]<br>
(specific activity of 15-20 Ci/mmol) diluted to 10 /xM<br>
with cold anandamide, and the membrane preparation<br>
(400 µg of frozen tissue per assay) are added<br>
successively. After 15 minutes at 25°C, the enzymatic<br>
reaction is stopped by adding 14 0 µl of<br>
chloroform/methanol (2:1). The mixture is stirred for<br>
10 minutes and then centrifuged for 15 minutes at<br>
3500 g. An aliquot (30 µl) of the aqueous phase<br>
containing the ethanolamine [1-3H] is counted by liquid<br>
scintillation.<br>
Under these conditions, the most active compounds of<br>
the invention exhibit IC50 values (concentration that<br><br>
inhibits 50% of the control enzymatic activity of FAAH)<br>
between 0.001 and 1 µM.<br>
It therefore appears that the compounds according to<br>
the invention have an inhibitory activity on the FAAH<br>
enzyme.<br>
The FAAH enzyme (Chemistry and Physics of Lipids,<br>
(2000), 108, 107-121) catalyses the hydrolysis of<br>
endogenous derivatives of amides and of esters of<br>
various fatty acids such as N-arachidonoylethanolamine<br>
(anandamide) , N-palmitoylethanolamine, N-oleylethanol-<br>
amine, oleamide or 2-arachidonoylglycerol. These<br>
derivatives exert various pharmacological activities by<br>
interacting, inter alia, with cannabinoid and vanilloid<br>
receptors.<br>
The compounds of the invention block this degradation<br>
pathway and increase the tissue content of these<br>
endogenous substances. They can be used in this respect<br>
in the prevention and treatment of pathologies in which<br>
endogenous cannabinoids and/or any other substrates<br>
metabolized by the FAAH enzyme are involved.<br>
Mention may, for example, be made of the following<br>
diseases and conditions:<br>
pain, in particular acute or chronic pain of neurogenic<br>
type: migraine, neuropathic pain including the forms<br>
associated with the herpesvirus and with diabetes;<br>
acute or chronic pain associated with inflammatory<br>
diseases: arthritis, rheumatoid arthritis,<br>
osteoarthritis, spondylitis, gout, vasculitis, Crohn's<br>
disease, irritable bowel syndrome;<br>
acute or chronic peripheral pain:<br>
dizziness, vomiting, nausea, in particular those<br>
subsequent to chemotherapy;<br>
eating disorders, in particular anorexia and cachexia<br>
of various natures;<br>
neurological and psychiatric pathologies: shaking,<br><br>
dyskinesia, dystonia, spasticity, obsessive compulsive<br>
disorders, Tourette's syndrome, all forms of depression<br>
and anxiety of any nature and origin, mood disorders,<br>
psychoses;<br>
acute and chronic neurodegenerative diseases:<br>
Parkinson's disease, Alzheimer's disease, senile<br>
dementia, Huntington's chorea, lesions related to<br>
cerebral ischemia and to cranial and medullary traumas;<br>
epilepsy;<br>
sleeping disorders, including sleep apnoea;<br>
cardiovascular diseases, in particular hypertension,<br>
cardiac arrhythmias, arteriosclerosis, heart attack,<br>
cardiac ischemias;<br>
renal ischemia;<br>
cancers: benign skin tumors, papillomas and brain<br>
tumors, prostate tumors, brain tumors (glioblastomas,<br>
medulloepitheliomas, medulloblastomas, neuroblastomas,<br>
tumors of embryonic origin, astrocytomas,<br>
astroblastomas, ependyomas, oligodendrogliomas, plexus<br>
tumors, neuroepitheliomas, epiphyseal tumors,<br>
ependymoblastomas, malignant meningiomas, sarcomatoses,<br>
malignant melanomas, schwannomas);<br>
immune system disorders, in particular autoimmune<br>
diseases: psoriasis, lupus erythematosus, connective<br>
tissue diseases or connectivitis, Sjogren's syndrome,<br>
ankylosing spondylarthritis, undifferentiated<br>
spondylarthritis, Behcet's disease, hemolytic auto-<br>
immune anemia, multiple sclerosis, amyotrophic lateral<br>
sclerosis, amyloses, transplant rejection, diseases<br>
affecting the plasmocyte line;<br>
allergic diseases: immediate or delayed hyper-<br>
sensitivity, allergic rhinitis or conjunctivitis,<br>
contact dermatitis;<br>
parasitic, viral or bacterial infectious diseases:<br>
AIDS, meningitis;<br>
inflammatory diseases, in particular articular<br>
diseases: arthritis, rheumatoid arthritis, osteo<br>
arthritis, spondylitis, gout, vasculitis, Crohn's<br>
disease, irritable bowel syndrome;<br><br>
osteoporosis ,-<br>
ocular conditions: ocular hypertension, glaucoma;<br>
pulmonary conditions: respiratory tract diseases,<br>
bronchospasms, coughs, asthma, chronic bronchitis,<br>
chronic respiratory tract obstruction, emphysema;<br>
gastrointestinal diseases: irritable bowel syndrome,<br>
intestinal inflammatory disorders, ulcers, diarrhea;<br>
urinary incontinence and bladder inflammation.<br>
The use of the compounds according to the invention for<br>
preparing a medicinal product for use in the treatment<br>
of the pathologies mentioned above is an integral part<br>
of the invention.<br>
The use of the following compounds for preparing a<br>
medicinal product for use in the treatment of the<br>
pathologies mentioned above is also an integral part of<br>
the invention:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-nitrophenyl 2 -[4-phenylmethoxy)phenyl]ethyl-<br>
carbamate,<br>
-	4-chloro-2-nitrophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	phenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	4-cyanopheny1 2-(4-methylphenyl)ethylcarbamate;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate,<br>
-	phenyl 2-[4-(2-ethyl-5,7-diimethyl-3H-imidazo-<br>
[4,5-b]pyridin-3-yl)phenyl]ethylcarbamate;<br><br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate.<br>
A subject of the invention is also medicinal products<br>
which comprise a compound of formula (I), or a salt, or<br>
else a hydrate or a solvate, that is pharmaceutically<br>
acceptable, of the compound of formula (I). These<br>
medicinal products find their use in therapeutics, in<br>
particular in the treatment of the pathologies<br>
mentioned above.<br>
A subject of the invention is also medicinal products<br>
which comprise a compound chosen from the list of<br>
compounds below, or a salt, or else a hydrate or a<br>
solvate, that is pharmaceutically acceptable, of this<br>
compound:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-nitrophenyl 2-[4-phenylmethoxy)phenyl]ethyl-<br>
carbamate,<br>
-	4-chloro-2-nitrophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	phenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	4-cyanophenyl 2-(4-methylphenyl)ethylcarbamate;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2-[4-(2-ethyl-5,7-diimethyl-3H-imidazo-<br>
[4,5-b]pyridin-3-yl)phenyl]ethylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br><br>
carbamate;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate.<br>
These medicinal products find their use in thera-<br>
peutics, in particular in the treatment of the<br>
pathologies mentioned above.<br>
According to another of its aspects, the present<br>
invention relates to pharmaceutical compositions<br>
containing, as active ingredient, at least one compound<br>
according to the invention. These pharmaceutical<br>
compositions contain an effective dose of a compound<br>
according to the invention, or a salt, or a hydrate, or<br>
a solvate, that is pharmaceutically acceptable, of said<br>
compound, and, optionally, one or more excipients that<br>
are pharmaceutically acceptable.<br>
According to another of its aspects, the present<br>
invention relates to pharmaceutical compositions<br>
containing, as active ingredient, at least one compound<br>
chosen from the list of compounds below. These<br>
pharmaceutical compositions contain an effective dose<br>
of a compound chosen from the list of compounds below,<br>
or a salt, or a hydrate, or a solvate, that is<br>
pharmaceutically acceptable, of said compound, and,<br>
optionally, one or more excipients that are pharma-<br>
ceutically acceptable:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-nitrophenyl 2-[4-phenylmethoxy)phenyl]ethyl-<br>
carbamate,<br>
-	4-chloro-2-nitrophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	phenyl 2- (3 ,4-dimethoxyphenyl) ethylcarbamate,-<br>
-	4-cyanophenyl 2-(4-methy1phenyl)ethylcarbamate;r<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate ;<br>
-	phenyl 4-chlorobenzylcarbamate;<br><br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo-<br>
[4,5-b]pyridin-3-yl)phenyl]ethylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate ;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate.<br>
Said excipients are chosen, according to the pharma-<br>
ceutical form and the method of administration desired,<br>
from the usual excipients that are known to those<br>
skilled in the art.<br>
In the pharmaceutical compositions of the present<br>
invention for oral, sublingual, subcutaneous, intra-<br>
muscular, intravenous, topical, local, intrathecal,<br>
intranasal, transdermal, pulmonary, ocular or rectal<br>
administration, the active ingredient of formula (I)<br>
above or one of the compounds below:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4-nitrophenyl 2-[4-phenylmethoxy)phenyl]ethyl-<br>
carbamate,<br>
-	4-chloro-2-nitrophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	4-nitrophenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	phenyl 2-(3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	4-cyanophenyl 2-(4-methylphenyl)ethylcarbamate;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br><br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo-<br>
[4, 5-b]pyridin-3-yl)phenyl]ethylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate;<br>
-	2,3,4,5,6-pentafluorophenyl 4-bromobenzylcarbamate;<br>
or its possible salt, solvate or hydrate, can be<br>
administered in unit administration form as a mixture<br>
with conventional pharmaceutical excipients, to animals<br>
and to human beings for the prophylaxis or the<br>
treatment of the disorders or of the diseases above.<br>
Suitable unit administration forms comprise oral<br>
administration forms such as tablets, soft or hard<br>
gelatin capsules, powders, granules, chewing gums and<br>
oral solutions or suspensions, sublingual, buccal,<br>
intratracheal, intraocular and intranasal admini-<br>
stration forms, forms for administration by inhalation,<br>
subcutaneous, intramuscular or intravenous<br>
administration forms, and rectal or vaginal admini-<br>
stration forms. For topical application, the compounds<br>
according to the invention can be used in creams,<br>
ointments or lotions.<br>
By way of example, a unit administration	form of a<br>
compound according to the invention in tablet form can<br>
comprise the following components:<br>
Compound according to the invention	50.0 mg<br>
Mannitol	223.75 mg<br>
Sodium croscarmellose	6.0 mg<br>
Corn starch	15.0 mg<br>
Hydroxypropylmethylcellulose	2.25 mg<br>
Magnesium stearate	3.0 mg<br>
Said unit forms contain doses so as to allow a daily<br>
administration of 0.01 to 20 mg of active ingredient<br><br>
per kg of bodyweight, according to the pharmaceutical<br>
form.<br>
There may be specific cases where higher or lower doses<br>
are appropriate, such doses are also part of the<br>
invention. According to the usual practice, the dosage<br>
suitable for each patient is determined by the<br>
physician according to the method of administration,<br>
and the weight and response to said patient.<br>
According to another of its aspects, the invention also<br>
relates to a method of treatment of the pathologies<br>
indicated above, which comprises the administration of<br>
an effective dose of a compound according to the<br>
invention, of one of its salts that are<br>
pharmaceutically acceptable, or of a solvate or a<br>
hydrate of said compound.<br><br>
WE. CLAIM:<br>
1. A compound of the formula (I);<br><br>
in which<br>
n represents an integer between 1 and 6; <br>
A is a group X;<br>
X represents a C1-2-alkylene group optionally<br>
substituted with one or more C1-12-alkyl, C3-7-cycloalkyl<br>
or C3-7-cycloalkyl-C1-6-alkylene groups;<br>
R1 represents a hydrogen atom, a halogen atom, or a<br>
hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-fluoroalkyl, C1-3-f luoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
R2 represents a hydrogen atom, a halogen atom, or a<br>
cyano, nitro, hydroxyl, C1-3-alkyl, C1-3-alkoxy, C1-3-<br>
thioalkyl, C1-3-fluoroalkyl, C1-3-fluoroalkoxy or C1-3-<br>
fluorothioalkyl group;<br>
or a group chosen from a phenyl, naphthalenyl biphenyl,<br>
phenylethylenyl, naphthylethylenyl, phenyloxy,<br>
phenylthxo, phehylsulfonyl, benzoyl phenylmethoxy,<br>
phenylethoxy, phenylpropoxy, naphthalenyloxy,<br>
naphthalenylmethoxy, naphthalenylethoxy, and<br>
naphthalenylpropoxy, and optionally substituted with<br>
one or more substituents chosen from a halogen atom,<br>
and the following groups: hydroxyl, cyano, nitro, C1-4-<br>
alkyl, C1-4-alkoxy, C1-4-thioalkyl, C1-3-fluoroalkyl, C1-3-<br>
fluoroalkoxy, C1-3-fluorothioalkyl, phenyloxy,<br>
benzyloxy, piperidyl, pyrrolidinyl, morpholinyl, NH2,<br><br>
NHR6, NR6R7; NHCOR6, COR6, CO2R6, SO2R6, -O-(C1-3-<br>
alkylene)-O-, 4-piperazinyl optionally substituted with<br>
a C1-3-alkyl or with a benzyl,<br>
R3 represents either a 2,2,2-trifluoroethyl group,<br>
or a phenyl group optionally substituted with one or<br>
more halogen atoms or cyano, nitro, C1-3-alkyl, C1-3-<br>
alkoxy, trifluoromethyl or. trifluoromethoxy groups,<br>
and<br>
R6 and R7 represent, independently of one another, a<br>
C1-3-alkyl group or a phenyl;<br>
with the proviso that:<br>
when R3 represents 2,2,2-trifluoroethyl group and the<br>
group - [A]n- represents a -CH2- group, then R1 is other<br>
thana hydrogen atom or a methoxy group; and<br>
when R3 represents an optionally substituted phenyl<br>
group and the group - [A]n- represents a -CH2-, -CH2CH2-,<br>
-CH(CH3)- or -CH(CH3)-CH2- group, then R1 is other than<br>
a hydrogen or chlorine atom or a methyl or methoxy<br>
group and R2 is other than a hydrogen atom; and<br>
wherein said compound is in the form of a base, or an<br>
addition salt with an acid.<br>
2. A process for preparing a compound of formula (I)<br><br>
in which R1, R2, R3, A and n are as defined according to <br>
claim 1,<br>
comprising the step of:<br>
reacting an amine of formula (II)<br><br><br>
in which R1, R2, n and A are as defined in formula (I) ,<br>
with a carbonate of formula (III)<br><br>
in which U represents a hydrogen atom or a nitro group<br>
and R3 is as defined in formula (I).<br>
3. A process for preparing a compound of formula (I)<br><br>
in which<br>
R1, R2, A and n are aa defined according to claim 1, and<br>
R3 represents a phenyl group optionally substituted<br>
with one or more halogen atoms, or cyano, nitro, C1-3-<br>
alkyl, C1-3-alkoxy, trifluoromethyl or trifluoromethoxy<br>
groups, comprising the step of<br>
reacting an amine of general formula (II)<br><br><br>
in which R1, R2, n and A are as defined in general<br>
formula (I) , with an aryl chloroformate of general<br>
formula (IIIa)<br><br>
in which R3 represents a phenyl group optionally<br>
substituted with one or more halogen atoms, or cyano,<br>
nitro, C1-3-alkyl, C1-3-alkoxy, trifluoromethyl or <br>
trifluoromethoxy groups.<br>
4.	A pharmaceutical composition comprising at least<br>
one compound of formula (I) as claimed in claim 1, in<br>
the form of a base, or a pharmaceutically acceptable<br>
salt, in combination with one or more pharmaceutically<br>
acceptable excipients.<br>
5.	The pharmaceutical composition as claimed in claim<br>
4, wherein compound of formula (I) is selected from the<br>
group consisting of:<br><br>
-	2, 2, 2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluorbethyl 4-methoxybenzylcarbamate;<br>
- 4-nitrophenyl 2- [4-(phenylmethoxy) phenyl] ethyl-<br>
carbamate ;<br>
-	4-chloro-2-nitrophenyl 2-(4-(chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 2 - (3,4 -dimethoxyphenyl) ethylcarbamate ;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate ;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br><br>
- 4 -fluorophenyl 2 -(4-methoxyphenyl)ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
-	phenyl 3-chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
-	4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl) phenyl]ethyl-<br>
carbamate; and<br>
-	2,3,4,5,6-pentafluorophenyl 4 -bromobenzylcarbamate;<br>
in the form of a base, or a pharmaceutically acceptable<br>
salt, hydrate or a solvate thereof.<br>
6. The compound of formula (I) as claimed in claim 1,<br>
in the form of a base, or a pharmaceutically acceptable<br>
salt thereof.<br>
7. The compound of formula (I) as claimed in claim 1,<br>
which is chosen from the following compounds:<br>
-	2,2,2-trifluoroethyl benzylcarbamate;<br>
-	2,2,2-trifluoroethyl 4-methoxybenzylcarbamate;<br>
-	4 -nitrophenyl 2-[4 - (pheriylmethoxy) phenyl] ethyl -<br>
carbamate;<br>
-	4-chloro-2-nitrophenyl 2-(4-(chlorophenyl)ethyl-<br>
carbamate ;<br>
-	phenyl 2 - (3,4-dimethoxyphenyl)ethylcarbamate;<br>
-	2,4,5-trichlorophenyl 2-(4-chlorophenyl)ethyl-<br>
carbamate;<br>
-	phenyl 4-chlorobenzylcarbamate;<br>
-	phenyl 4-methoxybenzylcarbamate;<br>
-	4-fluorophenyl 2-(4-methoxyphenyl) ethylcarbamate;<br>
-	phenyl 3-nitrobenzylcarbamate;<br><br>
-	4-cyanophenyl 4-methoxybenzylcarbamate;<br>
 - phenyl 3 -chlorobenzylcarbamate;<br>
-	phenyl 3,4-dichlorobenzylcarbamate;<br>
- 4-nitrophenyl 2-(4-hydroxyphenyl)ethylcarbamate;<br>
-	phenyl 2-[4-(2-amino-4-thiazolyl)phenyl]ethyl-<br>
carbamate; <br>
-	2,3, 4,5,6-pentafluorophenyl 4-bromobenzylcarbamate;<br>
in the form of a base, or a pharmaceutically acceptable<br>
salt thereof.	<br><br><br>
ARYLALKYLCARBAMATE DERIVATIVES AND PROCESSES FOR<br>
PREPARATION THEREOF<br><br><br><br>
(57) Abstract: The invention relates to a compound<br>
having general formula (I), wherein: n represents<br>
an integer of between 1 and 6; A is selected from<br>
one or more X, Y and/or Z groups; X represents an<br>
optionally-substituted C1-2-alkylene group; Y represents<br>
an optionally-substituted C2-alkenylene group or a<br>
-C<u>=</u>C- group; Z represents a C3-7-cycloalkyl<br>
group having formula (II) in which m represents an<br>
integer of between 1 and 5, and p and q represent integers<br>
and are defined such that p+q equals a number of between<br>
1 and 5; R1 represents a hydrogen atom, a halogen atom<br>
or a hydroxyl, cyano, nitro, C1-3-alkyl, C1-3-alkoxy,<br>
C1-3-thioalkyl, C1-3-fluoroalkyl, C1-3-fluoroalkoxy,<br>
C1-3-fluorothioalkyl group; R2 represents a hydrogen<br>
atom, a halogen atom or a cyano, nitro, hydroxyl,<br>
C1-3-alkyl, C1-3-alkoxy, C1-3-thioalkyl, C1-3-fluoroalkyl,<br>
C1-3-fluoroalkoxy, C1-3-fluorothioalkyl group, or an<br>
optionally-substituted aromatic or heteroaromatic group;<br>
R3 represents either a 2,2,2-trifluoroethyl group or an<br>
optionally-substituted phenyl group; and R6 and R7<br>
represent independently of each other a C1-3-alkyl group,<br>
a phenyl; said compound taking the form of a base, an<br>
acid addition salt, a hydrate or a solvate. The invention<br>
also relates to the use of the compound in therapeutics.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1ncGEucGRm" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1pbnRlcm5hdGlvbmFsIGV4bSByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-international exm report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDA3Nzkta29sbnAtMjAwNi1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">00779-kolnp-2006-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtQU1BTkRFRCBDTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtQVNTSUdOTUVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtQ09SUkVTUE9OREVOQ0UucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRVhBTUlOQVRJT04gUkVQT1JUIFJFUExZIFJFQ0lFVkVELnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-EXAMINATION REPORT REPLY RECIEVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRVhBTUlOQVRJT04gUkVQT1JULnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSAxMy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 13-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSAxMy0xLjIucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 13-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSAzLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtRk9STSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LWtvbG5wLTIwMDYtZm9ybTEzLlBERg==" target="_blank" style="word-wrap:break-word;">779-kolnp-2006-form13.PDF</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtR1BBLnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtR1JBTlRFRC1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtR1JBTlRFRC1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtR1JBTlRFRC1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtR1JBTlRFRC1GT1JNIDEucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtR1JBTlRFRC1GT1JNIDIucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtR1JBTlRFRC1TUEVDSUZJQ0FUSU9OLnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtT1RIRVJTLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-OTHERS-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtT1RIRVJTLnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtUEVUSVRJT04gVU5ERVIgUlVMRSAxMzcucGRm" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc5LUtPTE5QLTIwMDYtUkVQTFkgVE8gRVhBTUlOQVRJT04gUkVQT1JULnBkZg==" target="_blank" style="word-wrap:break-word;">779-KOLNP-2006-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDA3Nzkta29sbnAtMjAwNi5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-00779-kolnp-2006.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="264781-a-method-for-transmitting-data-from-a-send-device-to-various-subscriber-stations-in-a-universal-mobile-telecommunication-system.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="264783-method-for-controlling-the-graphical-display-of-a-portable-electronic-device.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>264782</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>779/KOLNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>04/2015</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>23-Jan-2015</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>21-Jan-2015</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>30-Mar-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SANOFI AVENTIS</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>174, AVENUE DE FRANCE, PARIS, 75013, FRANCE.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ABOUABDELLAH, AHMED</td>
											<td>2 RUE DES EGLANTIERS, F-94320, THIAIS, FRANCE.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>ALMARIO GARCIA, ANTONIO</td>
											<td>26 AVENUE ROGER SALENGRO, F-92290, CHATENAY, MALABRY, FRANCE.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 271/48</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/FR2004/002486</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-10-01</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>0311615</td>
									<td>2003-10-03</td>
								    <td>France</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/264782-arylalkylcarbamate-derivatives-and-processes-for-preparation-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:47:52 GMT -->
</html>
